Lucentis could still be a $2billion drug.
right now it is a 900M drug with 55% market share in wet AMD. avastin has 40% market share or a potential $750M of Lucentis sales.
off-label sales in DME and RVO account for <1% of lucnetis sales, but will be significant once they get a label.
There are a lot of rumors running around amondg the conspricacy theorist retinal specialists.
DNA is not going to divest lucentis. it is a remarkable drug, a blockbuster and RSs shoud be thanking Genentech for doing the research. Without it, they would ahve neither avastin or lucentis.
to be honest, i can't think of any drug for any indication that was such a leap forward in medical progress from the prvious therapy.
RSs are greedy
Market Data 
Markets 
AI
